BACKGROUND: Intra-operative tumor spill increases the risk of local recurrence of Wilms tumor, and adversely impacts relapse-free (RFS) and overall survival (OS) rates. METHODS: Surgical checklists, operative notes, institutional pathology reports, central pathology review and flow sheets of 602 patients registered between August 1986 and September 1994 on National Wilms Tumor Study-4 as randomized, followed or switched and coded as Final Stage II, favorable histology (FH) were reviewed. RFS and OS were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were estimated using the Cox model and tested for statistical significance by the log-rank test. RESULTS:Four hundred ninety-nine patients were found after review to have Stage II, FH Wilms tumor. The 8-year RFS percentages were 85.0% (95% confidence interval (CI): 81.1%, 88.1%) for those with no spill compared to 75.7% (65.8%, 83.2%) for those with spill. The 8-year OS percentages were 95.6% (93.1%, 97.3%) for those with no spill compared to 90.3% (82.2%, 94.9%) for those with spill. The HR for relapse among those with spill was 1.55 ((95%CI: 0.97,2.51), P = 0.067) and the HR for death was 1.94 ((0.92,4.09), P = 0.077). CONCLUSIONS:RFS and OS were lower for patients who had intra-operative tumor spill. The majority of NWTS Stage II, FH patients with intra-operative tumor spill have an overall excellent outcome when treated with two drug chemotherapy (vincristine and actinomycin D) and no abdominal irradiation.
RCT Entities:
BACKGROUND:Intra-operative tumor spill increases the risk of local recurrence of Wilms tumor, and adversely impacts relapse-free (RFS) and overall survival (OS) rates. METHODS: Surgical checklists, operative notes, institutional pathology reports, central pathology review and flow sheets of 602 patients registered between August 1986 and September 1994 on National Wilms Tumor Study-4 as randomized, followed or switched and coded as Final Stage II, favorable histology (FH) were reviewed. RFS and OS were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were estimated using the Cox model and tested for statistical significance by the log-rank test. RESULTS: Four hundred ninety-nine patients were found after review to have Stage II, FH Wilms tumor. The 8-year RFS percentages were 85.0% (95% confidence interval (CI): 81.1%, 88.1%) for those with no spill compared to 75.7% (65.8%, 83.2%) for those with spill. The 8-year OS percentages were 95.6% (93.1%, 97.3%) for those with no spill compared to 90.3% (82.2%, 94.9%) for those with spill. The HR for relapse among those with spill was 1.55 ((95%CI: 0.97,2.51), P = 0.067) and the HR for death was 1.94 ((0.92,4.09), P = 0.077). CONCLUSIONS: RFS and OS were lower for patients who had intra-operative tumor spill. The majority of NWTS Stage II, FHpatients with intra-operative tumor spill have an overall excellent outcome when treated with two drug chemotherapy (vincristine and actinomycin D) and no abdominal irradiation.
Authors: Daniel M Green; Jane M Lange; Eve M Peabody; Natalia N Grigorieva; Susan M Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544
Authors: N Breslow; G Churchill; J B Beckwith; D J Fernbach; H B Otherson; M Tefft; G J D'Angio Journal: J Clin Oncol Date: 1985-04 Impact factor: 44.544
Authors: G J D'Angio; A Evans; N Breslow; B Beckwith; H Bishop; V Farewell; W Goodwin; L Leape; N Palmer; L Sinks; W Sutow; M Tefft; J Wolff Journal: Cancer Date: 1981-05-01 Impact factor: 6.860
Authors: D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P E Grundy; P R Thomas; T Kim; S J Shochat; G M Haase; M L Ritchey; P P Kelalis; G J D'Angio Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: Rand N Wilcox Vanden Berg; Emily N Bierman; Megan Van Noord; Henry E Rice; Jonathan C Routh Journal: Urol Oncol Date: 2015-08-05 Impact factor: 3.498
Authors: Marry M van den Heuvel-Eibrink; Janna A Hol; Kathy Pritchard-Jones; Harm van Tinteren; Rhoikos Furtwängler; Arnauld C Verschuur; Gordan M Vujanic; Ivo Leuschner; Jesper Brok; Christian Rübe; Anne M Smets; Geert O Janssens; Jan Godzinski; Gema L Ramírez-Villar; Beatriz de Camargo; Heidi Segers; Paola Collini; Manfred Gessler; Christophe Bergeron; Filippo Spreafico; Norbert Graf Journal: Nat Rev Urol Date: 2017-10-31 Impact factor: 14.432
Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544
Authors: Annelies M C Mavinkurve-Groothuis; Frank van de Kracht; Rik Westland; Joanna A E van Wijk; Jacqueline J Loonen; Michiel F Schreuder Journal: Pediatr Nephrol Date: 2015-10-19 Impact factor: 3.714